Polarean Imaging PLC - Key patent in China secured
Polarean Imaging Plc has secured a Chinese patent for their Xenon MRI platform, which aids in visualizing pulmonary gas exchange and vascular function. This development positions the company for entry into the Chinese market. The new patent underscores Polarean's commitment to tackling lung diseases globally, especially significant given China's high respiratory disease burden.
Novacyt S.A. - Full year trading update
Novacyt S.A. has released an unaudited full year trading update for 2024, revealing 85% revenue growth to £19.6m, driven by the acquisition of Yourgene Health. The Group highlighted strong performance in Reproductive Health and Ranger® Technology, alongside operational optimizations. Novacyt remains financially robust with a £30.5m cash position and anticipates strategic growth plans in 2025.
Mindflair PLC - Net asset value update
Mindflair plc's investments in Sure Valley Ventures fund and Sure Ventures plc show significant growth. The NAV for SVV1 increased by 35% to £7,353,377, while the SV plc investment value rose to £1,489,768 as SV plc's share price increased. This growth is partly due to Infinite Reality's rising valuation.
Atlantic Lithium Ltd - Quarterly Activities and Cash Flow Report
Atlantic Lithium Limited has made significant strides in its flagship Ewoyaa Lithium Project in Ghana, receiving crucial permits including the Mine Operating Permit and Water Use Permit. Additionally, the company successfully raised A$10m to further advance toward the project's Final Investment Decision. Exploration activities continue in Côte d'Ivoire and Ghana.
Blencowe Resources - SAFELOOP Update
Blencowe Resources has completed significant testing work on samples from its Orom-Cross graphite project in Uganda, which further shows the compatibility of the company’s product with Project SAFELOOP, a European Union-led initiative under the €100 billion Horizon Europe Programme.
Nuformix PLC - £168,750 Placing
Nuformix plc, a pharmaceutical company focused on fibrosis and oncology via drug repurposing, announced a £168,750 placing through the issuance of 250 million new shares. Funds will support partnering discussions for its NXP002 program and general corporate purposes. Admission of new shares to the London Stock Exchange is expected around 5 February 2025.